UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 2024-12
Program Prior Authorization/Medical Necessity
Medication Bonjesta®* (doxylamine/pyridoxine extended-release), Diclegis®*
(doxylamine/pyridoxine delayed-release)
P&T Approval Date 4/2014, 4/2015, 3/2016, 4/2017, 7/2018, 9/2019, 10/2020, 11/2021,
12/2022, 1/2024
Effective Date 4/1/2024
1. Background:
Bonjesta and Diclegis are fixed dose combinations of doxylamine and pyridoxine approved
by the Food and Drug Administration (FDA) for the treatment of nausea and vomiting of
pregnancy in women who have not responded to conservative management.
2. Coverage Criteriaa:
1. Initial Authorization
a. Bonjesta* or Diclegis* will be approved based on all of the following criteria:
1. Diagnosis of nausea and vomiting associated with pregnancy
-AND-
2. Documented failure or contraindication to lifestyle modifications (e.g., diet,
avoidance of triggers)
-AND-
3. Documented trial and failure or contraindication to a five-day trial of over-the-
counter doxylamine taken together with pyridoxine (i.e., not a combined dosage
form, but separate formulations taken concomitantly).
Authorization will be issued for 9 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
*Bonjesta and Diclegis are typically excluded from coverage. Please refer to plan specifics to determine
exclusion status.
© 2024 United HealthCare Services, Inc.
1
3. Additional Clinical Rules:
• Supply limitations may be in place.
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
4. References:
1. Diclegis [package insert]. Princeton, NJ: Duchesnay USA, Inc.; June 2023.
2. "ACOG (American College of Obstetrics and Gynecology) Practice Bulletin: Nausea and
vomiting of pregnancy." Obstetrics and gynecology 2018; 131(1) e15-e30.
3. Herrell HE. Nausea and vomiting of pregnancy. Am Fam Physician 2014 Jun
15;89(12):965-970.
4. Bonjesta [package insert]. Princeton, NJ: Duchesnay USA, Inc.; October 2022.
Program Prior Authorization/Medical Necessity – Bonjesta and Diclegis
Change Control
4/2014 New Program
4/2015 Annual review with administrative changes.
3/2016 Increased initial authorization from 3 to 9 months and removed
reauthorization criteria.
7/2016 Added Indiana and West Virginia coverage information.
11/2016 Administrative change. Added California coverage information.
4/2017 Annual Review. Removed dosing for over-the-counter products.
Removed requirement for trial of dimenhydrinate and pyridoxine.
Updated references. State mandate reference language updated.
7/2018 Added Bonjesta to criteria. Updated to note Bonjesta and Diclegis are
typically excluded from coverage.
9/2019 Annual review. Updated references, added automation language, and
clarified trial/failure language with separate dosage forms.
10/2020 Annual review. Updated reference, clarified Diclegis dosage form.
11/2021 Annual review with no changes.
12/2022 Annual review with no changes.
1/2024 Annual review with no changes.
© 2024 United HealthCare Services, Inc.
2